J C Morrill1, C A Mebus, C J Peters. 1. US Army Medical Research Institute of Infectious Diseases, Applied Research Division, Fort Detrick, Frederick, MD 21702-5011, USA.
Abstract
OBJECTIVE: To examine effects of in utero inoculation with a mutagen-attenuated Rift Valley fever virus (RVFV) vaccine (RVF MP-12) on fetal bovids and to assess the safety and efficacy of calfhood vaccination with RVF MP-12. ANIMALS: 18 pregnant Hereford and Hereford-type cows in the third or fifth month of gestation, their progeny, and 25 calves from cows immunized with RVF MP-12 during pregnancy. PROCEDURE: Bovine fetuses were inoculated, via laparotomy, with 1 ml of RVF MP-12 containing 5 log10 plaque-forming units (PFU) of virus. Blood was obtained from newborn calves prior to their ingestion of colostrum. Immune-naive calves and calves born to RVF MP-12-vaccinated dams, ranging in age from 2 to 45 days, were vaccinated with RVF MP-12, and some were later challenge exposed with 1 ml of 5.7 log10 PFU of virulent RVFV strain ZH-501. Cows were monitored for viremia and antibody responses and for hematologic and serum biochemical alterations through parturition or abortion. RESULTS: Surviving in utero-vaccinated calves were healthy, with no noticeable defects. Except for 1 vaccine-inoculated fetus that died on postinoculation day 21, all in utero-vaccinated fetuses had serum neutralizing antibody titer > or = 1:20 at the time of delivery. All dams of in utero-vaccinated fetuses also developed neutralizing antibody titer. Calves born to cows vaccinated during gestation did not have antibody at birth, and all but 1 quickly acquired colostral antibody. Postparturient inoculation of immune-naive calves and calves with colostral antibodies resulted in no untoward effects, and all calves with detectable neutralizing antibodies were protected against virulent virus challenge exposure. CONCLUSIONS: Fetal death and abortion would be rare even if fetuses were exposed to RVF MP-12. The trauma and complications associated with in utero inoculation do not make this a practical method of immunization. RVF MP-12 was safe, immunogenic, and protective in calves as young as 2 days of age.
OBJECTIVE: To examine effects of in utero inoculation with a mutagen-attenuated Rift Valley fever virus (RVFV) vaccine (RVF MP-12) on fetal bovids and to assess the safety and efficacy of calfhood vaccination with RVF MP-12. ANIMALS: 18 pregnant Hereford and Hereford-type cows in the third or fifth month of gestation, their progeny, and 25 calves from cows immunized with RVF MP-12 during pregnancy. PROCEDURE: Bovine fetuses were inoculated, via laparotomy, with 1 ml of RVF MP-12 containing 5 log10 plaque-forming units (PFU) of virus. Blood was obtained from newborn calves prior to their ingestion of colostrum. Immune-naive calves and calves born to RVF MP-12-vaccinated dams, ranging in age from 2 to 45 days, were vaccinated with RVF MP-12, and some were later challenge exposed with 1 ml of 5.7 log10 PFU of virulent RVFV strain ZH-501. Cows were monitored for viremia and antibody responses and for hematologic and serum biochemical alterations through parturition or abortion. RESULTS: Surviving in utero-vaccinated calves were healthy, with no noticeable defects. Except for 1 vaccine-inoculated fetus that died on postinoculation day 21, all in utero-vaccinated fetuses had serum neutralizing antibody titer > or = 1:20 at the time of delivery. All dams of in utero-vaccinated fetuses also developed neutralizing antibody titer. Calves born to cows vaccinated during gestation did not have antibody at birth, and all but 1 quickly acquired colostral antibody. Postparturient inoculation of immune-naive calves and calves with colostral antibodies resulted in no untoward effects, and all calves with detectable neutralizing antibodies were protected against virulent virus challenge exposure. CONCLUSIONS:Fetal death and abortion would be rare even if fetuses were exposed to RVF MP-12. The trauma and complications associated with in utero inoculation do not make this a practical method of immunization. RVF MP-12 was safe, immunogenic, and protective in calves as young as 2 days of age.
Authors: John C Morrill; Richard C Laughlin; Nandadeva Lokugamage; Jing Wu; Roberta Pugh; Pooja Kanani; L Garry Adams; Shinji Makino; C J Peters Journal: Vaccine Date: 2013-08-27 Impact factor: 3.641
Authors: Myrna M Miller; Kristine E Bennett; Barbara S Drolet; Robbin Lindsay; James O Mecham; Will K Reeves; Hana M Weingartl; William C Wilson Journal: Clin Vaccine Immunol Date: 2015-06-03
Authors: Tetsuro Ikegami; Terence E Hill; Jennifer K Smith; Lihong Zhang; Terry L Juelich; Bin Gong; Olga A L Slack; Hoai J Ly; Nandadeva Lokugamage; Alexander N Freiberg Journal: J Virol Date: 2015-05-06 Impact factor: 5.103
Authors: John C Morrill; Richard C Laughlin; Nandadeva Lokugamage; Roberta Pugh; Elena Sbrana; William J Weise; L Garry Adams; Shinji Makino; C J Peters Journal: Vaccine Date: 2012-11-12 Impact factor: 3.641
Authors: Hoai J Ly; Shoko Nishiyama; Nandadeva Lokugamage; Jennifer K Smith; Lihong Zhang; David Perez; Terry L Juelich; Alexander N Freiberg; Tetsuro Ikegami Journal: Vaccine Date: 2017-10-20 Impact factor: 3.641